Meteorite identified after crashing into Georgia home
The space debris, now known as the "McDonough Meteorite," crashed through Earth's atmosphere on June 26, creating a large fireball before damaging a home outside of Atlanta.
Scott Harris, a planetary geologist and impact expert with UGA's Franklin College of Arts and Sciences, examined fragments that were recovered from the scene and traced their composition to around 4.5 billion years ago – long before the formation of Earth.
"It belongs to a group of asteroids in the main asteroid belt between Mars and Jupiter that we now think we can tie to a breakup of a much larger asteroid about 470 million years ago," Harris told the university's news service. "But in that breakup, some pieces get into Earth-crossing orbits, and if given long enough, their orbit around the sun and Earth's orbit around the sun end up being at the same place, at the same moment in time."
See The Objects Humans Left Behind On The Moon
The incoming meteor quickly broke apart when it sailed through Earth's atmosphere, with the largest piece that struck the Henry County home estimated to be the size of a cherry tomato.
Despite its small size, the meteorite was large enough to leave behind a hole in the roof, damage to HVAC ductwork and a significant dent in the wood floor.
No one was injured during the incident, but the impact was said to be as loud as a gunshot.
The UGA was granted access to study 23 grams of the 50 grams recovered from the home and is working in coordination with Arizona State University on further research.
According to the UGA, the event was the 27th meteorite that has been recovered in the Peach State.
"This is something that used to be expected once every few decades and not multiple times within 20 years," Harris stated. "Modern technology in addition to an attentive public is going to help us recover more and more meteorites."
Did The National Weather Service Capture A Photo Of Bigfoot During A Pennsylvania Storm Survey?
The latest update won't be the final word on the McDonough Meteorite, as Harris and his team plan to publish a paper detailing the object's composition and dynamics.
Additional recovered pieces of the meteorite are scheduled to go on display at the Tellus Science Museum near Atlanta.
The university did not state if the homeowner has completed repairs to his property, but damage caused by a meteorite usually falls under a standard insurance policy.Original article source: Meteorite identified after crashing into Georgia home
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
‘Remarkable' pancreatic cancer jab offers longer survival hope for patients
Pancreatic cancer patients have been given fresh hope after a new vaccine appeared to slow disease progression and increase survival. Researchers described the findings as 'remarkable' and have already started testing the efficacy of the jab among a larger group of pancreatic and bowel cancer patients. Pancreatic cancer has some of the poorest cancer survival rates because it is often not detected until it is advanced. Many patients see their cancer unremitting, even after undergoing traditional treatments including chemotherapy and radiotherapy. Now a new vaccine has been developed to help harness the body's immune system to find and attack cancer cells. The jab has shown promise in an early trial. Pancreatic and bowel cancers frequently carry a mutation in a gene called KRAS. This mutation plays a key role in tumour growth and scientists developed the jab to recognise and attack KRAS-mutant cancer cells. The jab is a new type of immunotherapy vaccine designed specifically to improve vaccine delivery to the lymph nodes, which act as filters for foreign substances in the body including cancer cells and infections. The phase 1 trial involved 20 patients with pancreatic cancer and five patients with bowel cancer. After an average follow-up time of almost 20 months, 68% of patients had developed strong immune responses specific to mutant KRAS tumour proteins. Though the study showed that some responded more favourably compared to others. Patients who had the strongest immune responses lived longer and stayed cancer free for longer than those with weaker responses. On average pancreatic cancer patients survived about two years and five months after receiving the vaccine, according to the study, which has been published in the journal Nature Medicine. At present, just three in 10 people diagnosed with the condition survive for a year. Meanwhile the average time before the disease returned, also known as recurrence free survival, was more than 15 months. While some cancer jabs are personalised to each patient, this jab, ELI-002 2P, has a single version which can be given to all patients. This 'off-the-shelf' version means that it can be manufactured in bulk and given more rapidly. Study lead Dr Zev Wainberg, from the University of California, Los Angeles, in the US, told the PA news agency: 'Pancreas cancer (patients) even after all standard treatments, such as chemotherapy and radiation, still have very high risks of the cancer coming back. 'Our results show in the group of patients who had profound immune responses (17/25 68%) achieved had longer survival than we have expected in this cancer, quite a remarkable finding to occur in a phase 1 trial.' He added: 'This is the first trial using a new platform, called AMP technology. 'The technology was invented by a material scientist engineer and immunology, Darrel Irvine, in his lab at MIT, and the platform was designed to improve vaccine delivery to lymph nodes which play a special role in the immune response.' Asked about next steps, he added: 'We launched a randomised phase 2 based on the initial results from the Amplify-201 study in January 2024. 'The accrual of the 144 patients participating was very rapid for this trial, which completed enrolment last December, and we are looking forward to the results as follow up continues.' Dr Chris Macdonald, head of research at the charity Pancreatic Cancer UK, said: 'Immunotherapy, and in particular cancer vaccines, hold so much opportunity in the treatment of pancreatic cancer, but so far the opportunity has not been realised. 'However in recent years, this is changing. This study is the latest in a rapidly progressing field. 'This early-stage study takes an important step, showing the effectiveness of an 'off-the-shelf' cancer vaccine, potentially breaking a reliance on having to generate a vaccine specifically for every individual patient. 'This approach saves time and is less costly and resource heavy, meaning more people could potentially benefit. 'The future is bright and if the momentum in this field continues to grow, more people could have the opportunity to benefit from immunotherapy, helping them to live better for longer.' Dr Dani Edmunds, research information manager at Cancer Research UK, added: 'Although we've helped to double cancer survival in the UK in the past 50 years, progress has not been the same for pancreatic cancer which remains hard to treat. 'Therefore, it's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer. 'The results suggest that the vaccine can boost the immune system against cancer in some people following standard treatment. 'These people survived and stayed free from disease for longer than people who didn't get as strong an immune boost following vaccination. 'Larger controlled trials are needed to confirm these initial findings about the benefits of the vaccine. 'More research is needed to understand why some people benefit from the vaccine while others don't so that we can make sure we're beating cancer for everyone.'
Gizmodo
3 minutes ago
- Gizmodo
‘Star Trek: Strange New Worlds' Almost Ended With a Movie
Just before the latest season of Star Trek: Strange New Worlds kicked off, we learned that the Enterprise's journey had set its end date: the show would conclude with a fifth and final season. However, that apparently wasn't always going to be the case, and the show nearly ended sooner. That's according to Rebecca Romijn, who plays Una Chin-Riley (a.k.a. Number One) on the show. Speaking this past weekend at the Star Trek convention STLV in Las Vegas, the actress—via TrekCore—revealed that initially, Strange New Worlds would've come to an end after its currently-in-production fourth season, before being capped off with a feature-length movie. According to Romijn, showrunners Henry Alonso Meyers and Akiva Goldsman were able to convince Paramount to change plans, resulting in the six-episode season five. At the very least that means Strange New Worlds fans are getting a little more Star Trek than originally planned (according to TrekCore, Romijn noted that the movie would've been 'just' two hours), even if it still is a truncated season compared to prior ones. But it also speaks to some of the tumult Star Trek has faced in recent years as Paramount has contracted the franchise after years of a streaming renaissance, and the studio itself prepared to seek new ownership (it was made official last week that Skydance's $8 billion takeover of the company had closed). Much of the Star Trek that helped define this new era for the series on streaming TV has wrapped up in the past few years, and with Strange New Worlds joining them in the next few, just one more series remains in production alongside it: Starfleet Academy, which will stream for at least two seasons. What, if any, Trek will come beyond that remains up in the air right now, although the hope of new ownership and a renewed focus on streaming could see a new generation of Trek shows emerge. Right now, much of the franchise's definitive future lies in film, just like Strange New Worlds' almost did. Patrick Stewart has spent the years since the conclusion of Star Trek: Picard suggesting a new film was in the works, and on the theatrical side of things, there's long been the perpetual hope of a fourth 'Kelvin Timeline' Trek film—but there's also Toby Haynes' planned 'origins' film detailing the early years of Starfleet post-First Contact. With all that in mind, a planned streaming movie conclusion to Strange New Worlds at least makes a little more sense. But only a little. After all, despite a rich cinematic legacy, Star Trek fans will likely always insist that the boldly going is just better in a long-form TV format. Who knows—maybe it would've been a better bet than a Section 31 movie turned out to be? Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.
WIRED
5 minutes ago
- WIRED
An AI Model for the Brain Is Coming to the ICU
Aug 11, 2025 11:00 AM The Cleveland Clinic and startup Piramidal are developing an AI model trained on brain wave data to monitor intensive care patients. The Cleveland Clinic is partnering with San Francisco-based startup Piramidal to develop a large-scale AI model that will be used to monitor patients' brain health in intensive care units. Instead of being trained on text, the system is based on electroencephalogram (EEG) data, which is collected via electrodes placed on the scalp and then read out by a computer in a series of wavy lines. EEG records the brain's electrical activity—and changes in this activity can indicate a problem. In an ICU setting, doctors scan EEG data looking for evidence of seizures, altered consciousness, or a decline in brain function. Currently, doctors rely on continuous EEG monitoring to detect abnormal brain activity in an ICU patient, but they can't monitor every individual patient in real time. Instead, EEG reports are typically generated every 12 or 24 hours and then analyzed to determine whether a patient is experiencing a neurological issue. It can take two to four hours to manually review a day's worth of brainwave data. 'This type of thing is time-consuming. It is subjective, and it is experience- and expertise-dependent,' says Imad Najm, a neurologist and director of the Epilepsy Center at the Cleveland Clinic's Neurological Institute. The system that the Cleveland Clinic and Piramidal are developing is designed to interpret continuous streams of EEG data and flag abnormalities in seconds so that doctors can intervene sooner. 'Our model plays that role of constantly monitoring patients in the ICU and letting the doctors know what's happening with the patient and how their brain health is evolving in real-time,' says Piramidal's chief product officer Kris Pahuja. Pahuja and CEO Dimitris Fotis Sakellariou founded Piramidal in 2023, with the goal of building a foundation model for the brain—an AI system that can read and interpret neural signals broadly across different people. Prior to this, Sakellariou spent 15 years as a neuroengineer and AI scientist doing EEG research. Pahuja worked on product strategy at Google and Spotify. Their startup, which is backed by Y Combinator, raised $6 million in seed funding last year. The company built its ICU brain model using publicly available EEG datasets, as well as proprietary EEG data from the Cleveland Clinic and other partnerships. Sakellariou says the model incorporates nearly a million hours of EEG monitoring data from 'dozens of thousands' of patients, both neurologically healthy and unhealthy. Brain activity patterns are extremely variable from person to person, so building a brain foundation model requires huge amounts of data to capture common patterns and features. 'The beauty of a foundation model is the same way ChatGPT can generalize text, it can adapt to your tone, it can adapt to your way of writing—our model is able to adapt to the brains of different people,' Sakellariou says. Currently, the Cleveland Clinic and Piramidal team is using retrospective patient data to fine tune the model. In the next six to eight months, they plan to test the model in a tightly controlled ICU environment with live patient data and a limited number of beds and doctors. From there, they aim to slowly roll out the software to the entire ICU. Eventually, the software will allow the hospital system to monitor hundreds of patients at once, Najm says. The slow rollout is to reduce the rate of false positives and false negatives—instances where the system misidentifies patients who don't have a severe event or failing to catch someone who does. The latter scenario especially is 'a big problem that keeps us awake at night,' Najm says. Piramidal did not comment on the model's current accuracy but said it has evaluated its technology against a network of doctors and has achieved 'human-like' performance. The company plans to publish data on the model's accuracy at a future date. While Piramidal's immediate focus is applying its brain foundation model to the ICU, Sakellariou and Pahuja also want to use it for epilepsy and sleep monitoring. Meanwhile, brain-computer interface company Synchron is developing a brain foundation model incorporating data from trial participants to make its system more accurate and generalizable to more users. There are also consumer applications of brain foundation models, such as using EEG earbuds to measure emotional states. Both medical and consumer applications raise questions about how brain data will be used and stored, as well as how and when it should be used. 'Advancements like this one highlight the need for anticipatory ethical frameworks that support responsible development and use of these technologies,' says Caroline Montojo, president and CEO of the Dana Foundation, a private philanthropic organization dedicated to neuroscience research. 'It's critical to bring in many different perspectives at early stages of technology design from multiple disciplines, including ethicists, social scientists, and legal scholars, as well as the lived experiences of patients.'
